Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Edoardo Spina, Maria Antonietta Barbieri, Giuseppe Cicala, Antonio Bruno & Jose de Leon. (2020) Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 31-44.
Read now
Read now
Yumiko Akamine & Masatomo Miura. (2018) An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opinion on Drug Metabolism & Toxicology 14:4, pages 429-434.
Read now
Read now
Jimmy Flarakos, Yancy Du, Helen Gu, Lai Wang, Heidi J. Einolf, Dung Y. Chun, Bing Zhu, Natalia Alexander, Adrienne Natrillo, Imad Hanna, Lillian Ting, Wei Zhou, Kiran Dole, Haiying Sun, Steven J. Kovacs, Daniel S. Stein, S. Ken Tanaka, Stephen Villano & James B. Mangold. (2017) Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline. Xenobiotica 47:8, pages 682-696.
Read now
Read now
Lori WE van der Schoor, Henkjan J Verkade, Folkert Kuipers & Johan W Jonker. (2015) New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 273-293.
Read now
Read now
Motoya Suzuki, Hiroshi Komura, Tomonori Yoshikawa, Seiji Enya, Akemi Nagao, Hiroaki Takubo & Motohiro Kogayu. (2014) Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (−/−) rats into absorption study of multiple transporter substrate. Xenobiotica 44:11, pages 1039-1045.
Read now
Read now
Domenico Italiano, Edoardo Spina & Jose de Leon. (2014) Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opinion on Drug Metabolism & Toxicology 10:11, pages 1457-1489.
Read now
Read now
Edoardo Spina & Jose de Leon. (2014) Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 10:5, pages 721-746.
Read now
Read now
Eve-Irene Lepist & Adrian S Ray. (2012) Renal drug–drug interactions: what we have learned and where we are going. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 433-448.
Read now
Read now
Jan-Shiang Taur, Christopher S. DesJardins, Edgar L. Schuck & Y. Nancy Wong. (2011) Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 41:4, pages 320-326.
Read now
Read now
Grzegorz Kofla, Vincent Turner, Bettina Schulz, Ulrike Storch, Daniela Froelich, Bénédicte Rognon, Alix T. Coste, Dominique Sanglard & Markus Ruhnke. (2011) Doxorubicin induces drug efflux pumps in Candida albicans. Medical Mycology 49:2, pages 132-142.
Read now
Read now
S.-F. Zhou. (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:7-8, pages 802-832.
Read now
Read now
Christoph Funk. (2008) The role of hepatic transporters in drug elimination. Expert Opinion on Drug Metabolism & Toxicology 4:4, pages 363-379.
Read now
Read now
Rainer Cermak. (2008) Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 4:1, pages 17-35.
Read now
Read now
Articles from other publishers (66)
Menglu Li, Yasunori Nawa, Seiichi Ishida, Yasunari Kanda, Satoshi Fujita & Katsumasa Fujita. (2022) Label-free chemical imaging of cytochrome P450 activity by Raman microscopy. Communications Biology 5:1.
Crossref
Crossref
Hironao Okubo, Hitoshi Ando, Kei Ishizuka, Jun-ichi Morishige, Kenichi Ikejima, Shuichiro Shiina & Akihito Nagahara. (2022) Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma. Journal of Pharmacological Sciences 148:1, pages 6-13.
Crossref
Crossref
Anne‐Margarethe Enge, Florian Kaltner, Christoph Gottschalk, Angelina Kin, Michael Kirstgen, Joachim Geyer, Anja These, Helen Hammer, Oliver Pötz, Albert Braeuning & Stefanie Hessel‐Pras. (2021)
Organic Cation Transporter I and Na
+
/taurocholate Co‐Transporting Polypeptide are Involved in Retrorsine‐ and Senecionine‐Induced Hepatotoxicity in HepaRG cells
. Molecular Nutrition & Food Research 66:2.
Crossref
Crossref
Stefano Fogli, Giulia Gianfilippo, Federico Cucchiara, Marzia Del Re, Laura Valerio, Rossella Elisei & Romano Danesi. (2021) Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. Critical Reviews in Oncology/Hematology 163, pages 103366.
Crossref
Crossref
Donald J. AbrahamUrban Fagerholm. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
14
.
Jiaming Li, Xiaoqian Wang, Chen Ning, Zhaoyu Wang, Yao Wang, Ming Zheng, Siliang Zhang, Yang Lu, Yongjie Zhang, Ning Li, Xijing Chen & Di Zhao. (2020) Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. European Journal of Clinical Pharmacology 76:8, pages 1125-1133.
Crossref
Crossref
Tomoko Ozeki, Mitsuji Nagahama, Kazuma Fujita, Akifumi Suzuki, Kiminori Sugino, Koichi Ito & Masatomo Miura. (2019) Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Scientific Reports 9:1.
Crossref
Crossref
Rong Shi, Zhangyao Xu, Xining Xu, Jingyi Jin, Yining Zhao, Tianming Wang, Yuanyuan Li & Yueming Ma. (2018) Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine. European Journal of Pharmaceutical Sciences.
Crossref
Crossref
Darren Michael Moss, Marco Siccardi & Catia Marzolini. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
49
85
.
Vikram Arya & Jennifer J. Kiser. (2016) Role of Transporters in Drug Development. The Journal of Clinical Pharmacology 56, pages S7-S10.
Crossref
Crossref
Jayabharathi Vaidyanathan, Kenta Yoshida, Vikram Arya & Lei Zhang. (2016) Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1. The Journal of Clinical Pharmacology 56, pages S59-S72.
Crossref
Crossref
Edoardo Spina, Francesco Pisani & Jose de Leon. (2016) Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacological Research 106, pages 72-86.
Crossref
Crossref
Mehran Mesgari Abbasi, Hadi Valizadeh, Hamed Hamishekar, Leila Mohammadnejad & Parvin Zakeri-Milani. (2016) The Effects of Cetirizine on P-glycoprotein Expression and Function In vitro and In situ. Advanced Pharmaceutical Bulletin 6:1, pages 111-118.
Crossref
Crossref
Jaehyun BaeMin Jung LeeEun Yeong ChoeChang Hee JungHye Jin WangMyoung Soo KimYu Seun KimJoong-Yeol ParkEun Seok Kang. (2016) Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study. Endocrinology and Metabolism 31:1, pages 161.
Crossref
Crossref
Edoardo Spina & Domenico Italiano. 2015. The Treatment of Epilepsy. The Treatment of Epilepsy
344
359
.
Jose de Leon. (2015) The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. Revista de Psiquiatría y Salud Mental (English Edition) 8:3, pages 167-188.
Crossref
Crossref
Jose de Leon. (2015) Efectos de los inductores antiepilépticos en la neuropsicofarmacología: una cuestión ignorada. Parte II: cuestiones farmacológicas y comprensión adicional. Revista de Psiquiatría y Salud Mental 8:3, pages 167-188.
Crossref
Crossref
Dirk Theile & Johanna Weiss. (2015) Comment on “Sweat but no gain”: Inhibiting proliferation of multidrug resistant cancer cells with “Ersatzdroges”. International Journal of Cancer 136:9, pages 2241-2242.
Crossref
Crossref
Danny Tsai, Janattul-Ain Jamal, Joshua S. Davis, Jeffrey Lipman & Jason A. Roberts. (2014) Interethnic Differences in Pharmacokinetics of Antibacterials. Clinical Pharmacokinetics 54:3, pages 243-260.
Crossref
Crossref
Kathleen E. Sampson, Amanda Brinker, Jennifer Pratt, Neetu Venkatraman, Yongling Xiao, Jim Blasberg, Toni Steiner, Maureen Bourner & David C. Thompson. (2015) Zinc Finger Nuclease–Mediated Gene Knockout Results in Loss of Transport Activity for P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells. Drug Metabolism and Disposition 43:2, pages 199-207.
Crossref
Crossref
Michaela Böhmdorfer, Alexandra Maier-Salamon, Juliane Riha, Stefan Brenner, Martina Höferl & Walter Jäger. (2014) Interplay of drug metabolizing enzymes with cellular transportersZusammenspiel von arzneistoffmetabolisierenden Enzymen mit zellulären Transportern. Wiener Medizinische Wochenschrift 164:21-22, pages 461-471.
Crossref
Crossref
Manoli Vourvahis, Juanzhi Fang, Heng Wee Choo & Jayvant Heera. (2014) The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. Clinical Pharmacology in Drug Development 3:3, pages 202-206.
Crossref
Crossref
Yuhua Li, Ling Huang, Xuezhen Zeng, Guoping Zhong, Mengjia Ying, Min Huang & Huichang Bi. (2014) Down-regulation of P-gp expression and function after Mulberroside A treatment: Potential role of protein kinase C and NF-kappa B. Chemico-Biological Interactions 213, pages 44-50.
Crossref
Crossref
Yu-hua Li, Hui-chang Bi, Ling Huang, Jing Jin, Guo-ping Zhong, Xu-nian Zhou & Min Huang. (2013) Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models. Acta Pharmacologica Sinica 35:2, pages 283-291.
Crossref
Crossref
Yuan Chen & Adrian J. Fretland. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
269
279
.
Elizabeth CM de Lange. 2014. Applied Pharmacometrics. Applied Pharmacometrics
407
449
.
Jibin Li, Ying Wang & Ismael J. Hidalgo. (2013) Kinetic Analysis of Human and Canine P-Glycoprotein-Mediated Drug Transport in MDR1-MDCK Cell Model: Approaches to Reduce False-Negative Substrate Classification. Journal of Pharmaceutical Sciences 102:9, pages 3436-3446.
Crossref
Crossref
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2013) How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice. European Journal of Internal Medicine 24:3, pages 217-221.
Crossref
Crossref
Yumiko Akamine, Norio Yasui-Furukori, Ichiro Ieiri & Tsukasa Uno. (2012) Psychotropic Drug–Drug Interactions Involving P-Glycoprotein. CNS Drugs 26:11, pages 959-973.
Crossref
Crossref
Alexander V. LyubimovRonald E. White. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
Thomayant Prueksaritanont & Cuyue Tang. (2012) ADME of Biologics—What Have We Learned from Small Molecules?. The AAPS Journal 14:3, pages 410-419.
Crossref
Crossref
Fabien Lamoureux, Nicolas Picard, Belkacem Boussera, François‐Ludovic Sauvage & Pierre Marquet. (2011) Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundamental & Clinical Pharmacology 26:4, pages 463-472.
Crossref
Crossref
Alexander V. LyubimovSouzan Yanni & Karel Allegaert. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
44
.
Maria Rosaria Muscatello, Edoardo Spina, Borwin Bandelow & David S. Baldwin. (2012) Clinically relevant drug interactions in anxiety disorders. Human Psychopharmacology: Clinical and Experimental 27:3, pages 239-253.
Crossref
Crossref
Adrian J. Fretland, Anshul Gupta, Peijuan Zhu & Catherine L. Booth‐Genthe. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
233
251
.
Praveen V. Balimane, Yong‐Hae Han & Saeho Chong. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
161
168
.
Junji Saruwatari, Norio Yasui-Furukori, Takenori Niioka, Yumiko Akamine, Ayaka Takashima, Sunao Kaneko & Tsukasa Uno. (2012) Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers. Journal of Clinical Psychopharmacology 32:2, pages 195-199.
Crossref
Crossref
Shaojun Shi & Ulrich Klotz. (2012) Drug Interactions with Herbal Medicines. Clinical Pharmacokinetics 51:2, pages 77-104.
Crossref
Crossref
Edoardo Spina, Gianluca Trifirò & Filippo Caraci. (2012) Clinically Significant Drug Interactions with Newer Antidepressants. CNS Drugs 26:1, pages 39-67.
Crossref
Crossref
Fionn E O'Brien, Timothy G Dinan, Brendan T Griffin & John F Cryan. (2011)
Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of
in vitro
and
in vivo
findings
. British Journal of Pharmacology 165:2, pages 289-312.
Crossref
Crossref
Carlo Nebbia. 2012. Veterinary Toxicology. Veterinary Toxicology
48
61
.
Steven R. Erickson, Jolene R. Bostwick & Sally K. Guthrie. 2011. Psychiatry and Heart Disease. Psychiatry and Heart Disease
194
210
.
Alaa H. Abuznait, Hisham Qosa, Nicholas D. O’Connell, Jessica Akbarian-Tefaghi, Paul W. Sylvester, Khalid A. El Sayed & Amal Kaddoumi. (2011) Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food and Chemical Toxicology 49:11, pages 2765-2772.
Crossref
Crossref
Ngoc H. On, Fang Chen, Martha Hinton & Donald W. Miller. (2011) Assessment of P-glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques. Pharmaceutical Research 28:10, pages 2505-2515.
Crossref
Crossref
Rashim Singh & Ming Hu. 2011. Oral Bioavailability. Oral Bioavailability
91
109
.
Min-Koo Choi, Qing-Ri Jin, Yeong-Lim Choi, Sung-Hoon Ahn, Myung-Ae Bae & Im-Sook Song. (2011) Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharmaceutics & Drug Disposition 32:3, pages 175-184.
Crossref
Crossref
Catia Marzolini, Manuel Battegay & David Back. 2011. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases
43
72
.
Donald J. AbrahamUrban Fagerholm. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
367
380
.
Elisabetta Chieli, Nadia Romiti, Idania Rodeiro & Gabino Garrido. (2010) In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chemico-Biological Interactions 186:3, pages 287-294.
Crossref
Crossref
Amin A. Nomeir. 2010. Early Drug Development. Early Drug Development
25
88
.
M. BALLENT, A. LIFSCHITZ, G. VIRKEL, L. MATE & C. LANUSSE. (2009) Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. Journal of Veterinary Pharmacology and Therapeutics 33:3, pages 252-259.
Crossref
Crossref
Louis Leung & Aram Oganesian. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
38
.
Jeannie M. Padowski & Gary M. Pollack. 2010. Multi-Drug Resistance in Cancer. Multi-Drug Resistance in Cancer
359
384
.
Chad L. Stoner, Michael R. Wester & Benjamin J. Burke. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
151
168
.
Ragini Vuppugalla, Sean Kim, Tatyana Zvyaga, Yong-hae Han, Praveen Balimane, Punit Marathe & A. David Rodrigues. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
585
624
.
Silvio Caccia, Silvio Garattini, Luca Pasina & Alessandro Nobili. (2009) Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies. Drug Safety 32:11, pages 1017-1039.
Crossref
Crossref
Adrian Lifschitz, Guillermo Virkel, Mariana Ballent, Juan Sallovitz & Carlos Lanusse. (2009) Combined use of ivermectin and triclabendazole in sheep: In vitro and in vivo characterisation of their pharmacological interaction. The Veterinary Journal 182:2, pages 261-268.
Crossref
Crossref
Elisabetta Chieli, Nadia Romiti, Idania Rodeiro & Gabino Garrido. (2009) In vitro effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. Food and Chemical Toxicology 47:11, pages 2703-2710.
Crossref
Crossref
Walter Jäger. 2009. Transporters as Drug Carriers. Transporters as Drug Carriers
325
347
.
Stacy S. ShordKanan Shah & Alvina Lukose. (2009) Drug—Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals. Integrative Cancer Therapies 8:3, pages 208-227.
Crossref
Crossref
C. Rosso Felipe, T. Veras de Sandes, E.L. Mandia Sampaio, S.I. Park, H. Tedesco SilvaJrJr & J.O. Medina Pestana. (2009) Clinical Impact of Polymorphisms of Transport Proteins and Enzymes Involved in the Metabolism of Immunosuppressive Drugs. Transplantation Proceedings 41:5, pages 1441-1455.
Crossref
Crossref
Sheng Deng, Xiao-Ping Chen, Dan Cao, Tao Yin, Zhi-Yong Dai, Jian Luo, Ling Tang & Yuan-Jian Li. (2009) Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clinical Therapeutics 31:6, pages 1256-1263.
Crossref
Crossref
Louis Leung & Aram Oganesian. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
89
126
.
KS Fenner, MD Troutman, S Kempshall, JA Cook, JA Ware, DA Smith & CA Lee. (2008) Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug. Clinical Pharmacology & Therapeutics 85:2, pages 173-181.
Crossref
Crossref
Chandra Prakash & Alfin D. N. Vaz. 2008. Nuclear Receptors in Drug Metabolism. Nuclear Receptors in Drug Metabolism
1
41
.
Thomas A. Baillie. (2007) Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism. Chemical Research in Toxicology 21:1, pages 129-137.
Crossref
Crossref